Navigation Links
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Date:6/8/2012

ily or 2 mg twice daily for 12 weeks. Patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy for an additional 12 weeks.

Patients completing Part B were eligible to continue in an open-label extension arm on either the 4 mg or 8 mg once daily doses of baricitinib for 52 additional weeks.

Part B of the study has completed and data analysis is underway. Patients are continuing to participate in the open-label long-term extension of the trial.

About JAK Inhibition

There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. These enzymes are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in RA patients. Cytokines such as interleukin-6, 12, and 23 signal through the JAK pathway and have been clinically validated as therapeutic targets in inflammatory diseases. Additional JAK-dependent cytokines have also been implicated in a number of inflammatory and autoimmune diseases suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions.

About Baricitinib

Baricitinib is an orally administered selective JAK1 and JAK2 inhibitor that is JAK3-sparing. Currently, baricitinib is in Phase II development as a treatment for rheumatoid arthritis and psoriasis.

In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for inflammatory and autoimmune diseases.

About Rheumatoid Arthritis

The disease is characterized by abnormal immune mechanisms that lead to joint inflammation and swelling with progressive destruction of joints. In addition to affecting the joints, RA can also affect connective tissue in the skin and organs of the body. [1]

Current treatment of RA includes the use of non-steroidal anti-inflam
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
2. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. DiversityInc Names Lilly a Top Company for Diversity
7. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... applications made a lot of progress in the ... are now accepted in high-reliability environments, and are ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... Aug. 30 Hologic, Inc. (Nasdaq: HOLX ... Executive Officer, will present at the 2010 Morgan Stanley ... 2:45 p.m. (Eastern). Interested parties are invited ... investor presentation on the investor section of the company,s ...
... AMEX: DDD ) today announced that it has ... support for the Company,s new line of extended-release nutritional and ... www.emersongroup.com ), headquartered in Wayne, Pa., is a consumer products ... to companies in the United States market.  ...
Cached Medicine Technology:SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 2SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 3
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
(Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
Breaking Medicine News(10 mins):Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... first astronaut, involved in a 25 million dollar space ... on the growth of cancer cells in outer space, ... conduct research on cells, bacteria and the crystallisation of ... Molecule Medical Institute at the National University of Malaysia. ...
... College London have found that injections of stem cells ... of children with brittle bone disease , osteogenesis imperfecta ... foetuses by DNA testing or ultrasound, disrupts collagen production, ... the condition suffer fractures while in the womb, and ...
... on Wednesday proposed uprooting excess vineyards and launching an ... strategy aimed at soaking up glut and countering New ... that the European Union's annual wine budget of 1.3 ... "a very inefficient way" despite huge challenges facing the ...
... cat allergen is associated with greater bronchial responsiveness (BR) ... they are not specifically allergic to cats. This suggests ... allergic individuals, regardless of their specific allergies. ... lead author of the study. We presupposed that we ...
... Makes a Lot of Noise has had to turn it ... effect this week . But where there are 8,000,000 New ... of Environmental Protection has a phone line, 311, for quality-of-life ... callers say, is distracting, annoying, shrill, dull or rattling -- ...
... after tests on three dead swans in the northeast confirmed an ... fatal to humans. ,"France is not threatened by ... moment, a human contamination from the H5N1 virus," Health Minister Roselyne ... as the great flu epidemic that followed the war of 1914, ...
Cached Medicine News:Health News:EU Aims to Shake Up Wine Industry With Root-and-branch Reform 2Health News:Cat Exposure Increases Bronchial Responsiveness 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 3Health News:France Steps Up Vigilance After Bird Flu Outbreak 2
CRP high sensitivity calibrator series...
Inquire...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Medicine Products: